Inclisiran (Leqvio): How It Compares to Statins for LDL Reduction

What Is Inclisiran and How Does It Work?

Inclisiran is the first small interfering RNA (siRNA) approved specifically to lower LDL cholesterol. Rather than blocking an enzyme directly, it silences the gene that produces PCSK9, a protein that degrades LDL receptors in the liver. With PCSK9 suppressed, more LDL receptors remain on liver cell surfaces, pulling more LDL out of the bloodstream. A single 284 mg subcutaneous dose sustains PCSK9 suppression for roughly six months, which is why the maintenance schedule requires only two injections per year after the initial loading doses at day 1 and day 90.

This mechanism differs fundamentally from statins, which inhibit HMG-CoA reductase, and from ezetimibe, which blocks intestinal cholesterol absorption via the NPC1L1 transporter. Because inclisiran acts downstream of both of those targets, combining it with a statin or ezetimibe produces additive LDL reduction without pharmacokinetic interactions between the drugs [1].

The FDA approved inclisiran (Leqvio) on December 22, 2021, for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who need additional LDL-C lowering on top of maximally tolerated statin therapy [2].

The ORION Trial Program: What the Evidence Actually Shows

Three phase 3 randomized controlled trials form the core evidence base for inclisiran.

ORION-10 enrolled 1,561 patients with ASCVD already receiving maximum-tolerated statin therapy. At 510 days, inclisiran reduced LDL-C by a time-averaged 52.3 percent versus placebo (P<0.001). The placebo group showed a 0.1 percent change [3].

ORION-9 studied 482 patients with heterozygous familial hypercholesterolemia. Time-averaged LDL-C reduction was 47.9 percent with inclisiran versus a 3.6 percent increase in the placebo arm (P<0.001) [4].

ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents across European sites. Time-averaged LDL-C reduction reached 49.9 percent (P<0.001) [5].

Across all three trials, injection-site reactions occurred in 2.6 percent of inclisiran patients versus 0.9 percent with placebo, but were mostly mild and transient. No excess of muscle-related adverse events, liver enzyme elevations, or diabetes signals appeared compared with placebo.

A 2023 meta-analysis published in the European Heart Journal pooling ORION-9, ORION-10, and ORION-11 (N=3,660) confirmed a mean LDL-C reduction of 50.5 percent and found no significant differences in serious adverse events between inclisiran and placebo groups over approximately 18 months [6].

Atorvastatin (Lipitor): Still the Most Prescribed Statin

Atorvastatin remains the single most prescribed lipid-lowering drug worldwide. It inhibits hepatic HMG-CoA reductase, reducing de novo cholesterol synthesis and upregulating LDL-receptor expression as a compensatory response. High-intensity doses (40 mg and 80 mg daily) typically lower LDL-C by 49 to 57 percent from baseline as monotherapy [7].

The landmark TNT trial (N=10,001) demonstrated that atorvastatin 80 mg daily reduced major cardiovascular events by 22 percent compared with atorvastatin 10 mg daily over 4.9 years [8]. The ACC/AHA 2019 guideline on the management of blood cholesterol designates atorvastatin 40 to 80 mg as a high-intensity statin therapy and recommends it as first-line treatment for most adults with ASCVD or a 10-year cardiovascular risk of 7.5 percent or greater [9].

Where atorvastatin falls short: approximately 50 percent of patients on maximum-dose statin therapy still do not reach an LDL-C below 70 mg/dL, the guideline target for very-high-risk ASCVD patients. That gap is precisely where inclisiran fits [9].

Common side effects of atorvastatin include myalgia (reported in 5 to 10 percent of patients in real-world registries), mild transaminase elevations, and a modest increase in new-onset type 2 diabetes risk of roughly 9 to 12 percent in susceptible individuals at high doses. The 80 mg dose carries an FDA warning about increased risk of myopathy when combined with certain medications [7].

Rosuvastatin (Crestor): The Highest-Potency Oral Statin

Rosuvastatin achieves the largest LDL-C reductions of any approved statin at standard doses. The 40 mg daily dose produces LDL-C reductions of 55 to 63 percent from untreated baseline, slightly exceeding atorvastatin 80 mg in head-to-head comparisons [10].

JUPITER (N=17,802) showed that rosuvastatin 20 mg daily reduced major cardiovascular events by 44 percent versus placebo in apparently healthy adults with elevated high-sensitivity C-reactive protein (P<0.001), demonstrating benefit even in patients with LDL-C below 130 mg/dL at baseline [11].

Rosuvastatin is predominantly renally excreted (about 90 percent excreted unchanged in feces, with minimal CYP450 metabolism), giving it a lower drug-interaction profile compared with atorvastatin, which is metabolized by CYP3A4. Patients taking strong CYP3A4 inhibitors such as clarithromycin or certain HIV antiretrovirals may tolerate rosuvastatin better than atorvastatin for that reason.

The diabetes risk associated with rosuvastatin appears similar to atorvastatin: the JUPITER trial noted an 18 percent increase in physician-reported diabetes in the rosuvastatin arm, consistent with the class effect [11]. Patients with fasting glucose in the pre-diabetic range warrant glycemic monitoring after starting any high-intensity statin.

Simvastatin (Zocor): Effective But Dose-Limited

Simvastatin was among the first statins proven to reduce cardiovascular mortality. The 4S trial (N=4,444, 1994) showed simvastatin reduced total mortality by 30 percent and major coronary events by 34 percent over 5.4 years in patients with established coronary disease and elevated baseline LDL-C [12].

At 40 mg daily, simvastatin produces LDL-C reductions of 35 to 41 percent. The 80 mg dose achieves 42 to 47 percent reduction but carries an FDA-mandated dose restriction issued in 2011: simvastatin 80 mg may only be continued in patients who have already tolerated it for 12 months without myopathy, and it must never be initiated in new patients. This restriction stems from a seven-fold higher myopathy risk at 80 mg compared with 20 mg, confirmed in the SEARCH trial (N=12,064) [13].

Simvastatin is also metabolized by CYP3A4, and numerous drug interactions require dose caps. For example, concomitant amlodipine limits simvastatin to 20 mg daily; concomitant diltiazem or verapamil caps the dose at 10 mg. Given these constraints and the availability of rosuvastatin and atorvastatin, many guidelines now relegate simvastatin to a moderate-intensity option rather than a first choice for high-intensity therapy [9].

Ezetimibe (Zetia): The Preferred Non-Statin Add-On Before Inclisiran

Ezetimibe blocks the NPC1L1 cholesterol transporter in the small intestine, reducing dietary and biliary cholesterol absorption by approximately 54 percent. As monotherapy, it lowers LDL-C by 18 to 22 percent. Added to a statin, it provides an incremental 15 to 20 percentage-point reduction in LDL-C [14].

IMPROVE-IT (N=18,144) demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite cardiovascular endpoint by 6.4 percent relative to simvastatin alone over a median 6 years (P=0.016). The absolute risk reduction was modest: 2 percentage points [15]. The ACC/AHA 2019 guideline describes ezetimibe as a reasonable next step in very-high-risk patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy [9].

Ezetimibe costs roughly $5 to $20 per month in generic form, making it by far the least expensive add-on option. Guidelines generally recommend a trial of ezetimibe before escalating to PCSK9 inhibitors including inclisiran, both on cost grounds and because many patients reach goal with that combination.

Inclisiran vs. Statin Therapy: A Direct Comparison

No head-to-head randomized trial has directly compared inclisiran with atorvastatin or rosuvastatin as a first-line agent. The ORION trials all enrolled patients already receiving maximally tolerated statins, so inclisiran's place in current guidelines is as an add-on, not a replacement.

Here is what the data show about LDL-C reduction by drug and dose, expressed as approximate reductions from untreated baseline or from treated baseline where noted:

• Atorvastatin 80 mg: 49 to 57 percent from untreated baseline [7]
• Rosuvastatin 40 mg: 55 to 63 percent from untreated baseline [10]
• Simvastatin 40 mg: 35 to 41 percent from untreated baseline [12]
• Ezetimibe 10 mg added to statin: additional 15 to 20 percentage points [14]
• Inclisiran 284 mg twice yearly added to statin: additional 50 percent from statin-treated baseline [3]

A patient on atorvastatin 80 mg with an LDL-C of 100 mg/dL might expect to reach roughly 50 mg/dL with the addition of inclisiran, compared with roughly 80 mg/dL with ezetimibe alone. For very-high-risk patients with a guideline target of LDL-C below 55 mg/dL (per the 2019 ESC/EAS guideline), inclisiran may be necessary to reach goal when statins and ezetimibe are insufficient [16].

HealthRX Clinical Escalation Framework for LDL-C Management:

Step 1. Start with high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg). Reassess LDL-C at 6 to 12 weeks. Step 2. If LDL-C remains above 70 mg/dL in ASCVD patients or above 100 mg/dL in primary prevention patients, add ezetimibe 10 mg daily. Step 3. Recheck LDL-C at 6 to 12 weeks. If still above goal and patient has confirmed ASCVD or HeFH, discuss inclisiran or a monoclonal PCSK9 inhibitor (evolocumab or alirocumab) with your prescribing clinician. Step 4. For statin-intolerant patients with confirmed muscle toxicity on two or more statins, inclisiran may be considered alongside ezetimibe as the backbone lipid therapy, though this is an off-label use outside the current FDA indication.

Inclisiran vs. Monoclonal PCSK9 Inhibitors

Two monoclonal antibodies also target PCSK9: evolocumab (Repatha) and alirocumab (Praluent). Both require injections every two to four weeks, compared with inclisiran's twice-yearly schedule. LDL-C reductions are similar: evolocumab produced 59 percent mean LDL-C reduction in FOURIER (N=27,564), while inclisiran produces approximately 50 percent reduction in ORION trials [17].

FOURIER demonstrated a 15 percent relative risk reduction in major adverse cardiovascular events with evolocumab over a median 2.2 years (P<0.001), establishing cardiovascular outcome benefit for the monoclonal antibody class [17]. A dedicated cardiovascular outcomes trial for inclisiran, ORION-4 (N=15,000, ongoing), is expected to report primary results in 2026. Until those data are available, inclisiran's cardiovascular event reduction is inferred from LDL-C lowering rather than directly demonstrated.

The ACC/AHA 2022 Guideline on Coronary Artery Disease states: "For patients with very high-risk ASCVD, it is reasonable to add ezetimibe to maximally tolerated statin therapy. If LDL-C remains 70 mg/dL or higher, it is reasonable to further add a PCSK9 inhibitor." [18] The guideline does not yet distinguish between siRNA-based inclisiran and monoclonal PCSK9 inhibitors as preferred agents, treating them as a class for this indication.

Dosing, Administration, and Access

Inclisiran is supplied as a 284 mg/1.5 mL solution in a pre-filled syringe. A clinician administers it as a subcutaneous injection in the abdomen, upper arm, or thigh. The schedule is:

• Day 1 (first dose)
• Day 90 (plus or minus 2 weeks)
• Every 6 months thereafter

Because inclisiran requires office administration, it qualifies for Part B billing in Medicare in the United States, which affects how providers order it. Patients with commercial insurance typically face prior authorization requirements, and most payers require documented failure or intolerance to maximally tolerated statin therapy plus ezetimibe before approving inclisiran.

The list price is approximately $3,600 per dose, or about $7,200 per year. Novartis offers a patient assistance program through Leqvio Connect for commercially insured and uninsured patients who meet income criteria.

Statin Intolerance: Does Inclisiran Fill the Gap?

Statin-associated muscle symptoms (SAMS) occur in an estimated 5 to 29 percent of patients in real-world practice, though blinded rechallenge studies suggest the nocebo effect accounts for a substantial fraction of those reports. The SAMSON trial (N=200) found that 90 percent of symptom burden during statin therapy was reproduced by placebo, suggesting true pharmacologic myopathy is considerably less common than reported [19].

For patients with genuine statin intolerance confirmed on two or more statins, options include:

• Rosuvastatin 5 mg every other day (retains partial LDL reduction with lower myopathy risk)
• Ezetimibe 10 mg daily (no muscle mechanism, 18 to 22 percent LDL reduction)
• Bempedoic acid 180 mg daily (ATP-citrate lyase inhibitor; approximately 18 percent LDL reduction; CLEAR Outcomes trial, N=13,970, showed 13 percent reduction in MACE) [20]
• Inclisiran (off-label in statin intolerance; phase 3 data as an add-on to non-statin therapies are limited)

The current FDA label for inclisiran requires it to be used as an adjunct to diet and maximally tolerated statin therapy. Using it as sole lipid therapy in statin-intolerant patients falls outside the approved indication and should involve shared decision-making with a cardiologist or lipidologist.

Monitoring, Drug Interactions, and Safety

Inclisiran has no clinically significant drug-drug interactions identified to date. It is taken up selectively by hepatocytes via the ASGR1 receptor and undergoes intracellular metabolism to inactive nucleotides; it does not interact with CYP450 enzymes, P-glycoprotein, or renal transporters [2].

Liver function testing and creatine kinase monitoring are not required by the prescribing information, unlike with high-dose simvastatin or combinations prone to myopathy. Renal dosing adjustment is not needed for mild to moderate chronic kidney disease. Patients with severe hepatic impairment (Child-Pugh C) have not been studied and should not receive inclisiran until data are available.

Pregnancy and lactation: inclisiran is contraindicated in pregnancy. The prescribing information states that animal studies showed fetal harm at doses relevant to the human dose and that LDL-C is required for normal fetal development. Females of reproductive potential should use effective contraception during treatment and for approximately eight months after the last dose [2].

Who Is the Ideal Candidate for Inclisiran?

Based on the ORION trial inclusion criteria and FDA labeling, the typical candidate for inclisiran:

• Has established ASCVD (prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease) OR has HeFH
• Is already on maximally tolerated statin therapy for at least 3 months
• Has an LDL-C above 70 mg/dL (very-high-risk ASCVD) or above 100 mg/dL (HeFH without ASCVD) despite statin plus ezetimibe
• Prefers a twice-yearly injection over daily pills, or has demonstrated difficulty with oral medication adherence

Adherence is where inclisiran may hold a practical advantage over daily oral statins. A 2022 real-world adherence study of statins in the United Kingdom found that only 53 percent of patients were still taking their statin at 12 months [21]. Twice-yearly injections administered in a clinical setting effectively guarantee adherence during the dosing interval, a feature with no equivalent in the oral statin class.